Arrowhead Pharmaceuticals (ARWR)

Executive Summary

Arrowhead Pharmaceuticals is a publicly traded biotechnology company pioneering RNA interference (RNAi) therapeutics through its proprietary TRiM™ platform. The company focuses on silencing disease-causing genes across multiple organ systems, with a lead pipeline centered on plozasiran (ARO-APOC3), an investigational RNAi therapy targeting apoC-III for severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS). Plozasiran has demonstrated promising Phase 2 data, and two pivotal Phase 3 trials are nearing completion: one in FCS (NCT05089084) and another in hypertriglyceridemia (NCT06347133). These studies address significant unmet needs in lipid disorders, where current treatments are limited. Arrowhead's platform also supports earlier-stage programs, but near-term value hinges on plozasiran's success. With a strong balance sheet and a history of strategic partnerships, the company is well-positioned to advance its RNAi pipeline. However, dependence on plozasiran and regulatory outcomes remain key risks.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 data readout for plozasiran in familial chylomicronemia syndrome (FCS)75% success
• Q4 2026Phase 3 data readout for plozasiran in hypertriglyceridemia70% success
• H1 2027Potential U.S. NDA filing for plozasiran in FCS, if Phase 3 results are positive60% success